31st week of 2009 patent applcation highlights part 32 |
Patent application number | Title | Published |
20090191118 | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 - The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells. | 2009-07-30 |
20090191119 | CANCEROUS DISEASE MODIFYING ANTIBODIES - The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells. | 2009-07-30 |
20090191120 | CANCEROUS DISEASE MODIFYING ANTIBODIES - The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells. | 2009-07-30 |
20090191121 | Targeting and Imaging Tumor Vasculature Using Conjugates That Bind to Aminophospholipids - Disclosed is the surprising discovery that aminophospholipids, such as phosphatidyserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression. | 2009-07-30 |
20090191122 | METHOD FOR PURIFICATION OF 225AC FROM IRRADIATED 226RA-TARGETS - The present invention describes a method for purification of | 2009-07-30 |
20090191123 | NOVEL IMAGING AGENTS - The present invention provides a novel imaging agent suitable for the non-invasive visualization of fibrosis. A precursor for the preparation of the imaging agent is also provided by the invention, as well as a pharmaceutical composition comprising the imaging agent and a kit for the preparation of the pharmaceutical composition. In a further aspect, use of the imaging agent for in vivo imaging and in the preparation of a medicament for the diagnosis of a condition which comprises fibrosis is provided. | 2009-07-30 |
20090191124 | PDGF-RBeta BINDERS - Provided herein are PDGF-Rβ imaging agents that are polypeptides labeled with a signal generator (e.g., paramagnetic label, a radionuclide, or a fluorophore), wherein the imaging agents bind specifically to PDGFR-β. Also provided are in vivo imaging methods using the imaging agents. | 2009-07-30 |
20090191125 | Diagnostic and Therapeutic Alkyl Piperidine/Piperazine Compounds and Process - Piperidine or piperazine compounds useful for treating neurodegenerated diseases characterized by the lack of dopamine neurons activity or for imaging the dopamine neurons are provided. The compounds are characterized by the formulae: | 2009-07-30 |
20090191126 | PEPTIDE AND MULTIVALENT PEPTIDE CONJUGATE FOR DIAGNOSIS AND TREATMENT OF VASCULAR PLAQUES - This invention encompasses compositions and methods for treating and imaging vulnerable plaque and other inflamed regions in a subject. | 2009-07-30 |
20090191127 | OMENTUM AND USE THEREOF - In some embodiments, mammalian omentum and methods of using the same for treating symptoms and/or conditions related to dementia are provided. In addition, a composition comprising the omentum tissue and/or the extract thereof is described in some embodiments. In some other embodiments, methods of formulating and administering the composition are also provided. In addition, a cultured cell system to culture cells and/or tissues of the omentum is described. Some aspects of embodiments provide methods of identifying one or more biological agent from the omentum tissue. In another aspect of the embodiments, methods of testing the effect of stimulation omentum in treating dementia conditions are described. | 2009-07-30 |
20090191128 | CORE-SHELL NANOPARTICLES FOR THEARAPY AND IMAGING PURPOSES - The invention relates to nanoparticles coated with an inorganic nanoscale material herein referred to as core-shell nanoparticle, in which the core material has a wider band gap than the shell material. The described core-shell nanoparticles are very suitable for the application in photodynamic therapy due to their enhanced energy transfer ability. | 2009-07-30 |
20090191129 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS - This invention relates to novel compounds suitable for labelling or already labelled by | 2009-07-30 |
20090191130 | DE NOVO SYNTHESIS OF BACTERIOCHLORINS - A method of making a bacteriochlorin is carried out by condensing a pair of compounds of Formula II | 2009-07-30 |
20090191131 | USE OF PARTICULATE CONTRAST AGENTS IN DIAGNOSTIC IMAGING FOR STUDYING PHYSIOLOGICAL PARAMATERS - The present invention relates to a method of imaging of an animate human or non-human animal body, which method comprises: administering parenterally to said body a particulate material comprising a matrix or membrane material and at least one contrast generating species, which matrix or membrane material is responsive to a pre-selected physiological parameter whereby to alter the contrast efficacy of said species in response to a change in the value of said parameter; generating image data of at least part of said body in which said species is present; and generating therefrom a signal indicative of the value or variation of said parameter in said part of said body. The invention also relates to contrast media for imaging a physiological parameter. | 2009-07-30 |
20090191132 | Coded medication and methods of preparing same for identification and distinguishment - A selected substance is dissolved into a given injectable fluid medication having an initial clear visual appearance. The selected substance is selected from a group of substances which, when dissolved in the injectable fluid medication, will alter the clear appearance to produce a non-clear or altered visual appearance. The altered visual appearance could be a color, which, by code, identifies the given injectable fluid medication, and distinguishes the given injectable fluid medication from a different injectable fluid medication, the clear visual appearance of which has been altered by dissolving another selected substance to produce a colored visual appearance different from the color of the altered visual appearance of the given injectable fluid medication. | 2009-07-30 |
20090191133 | MODULATION OF STAT 6 EXPRESSION FOR THE TREATMENT OF AIRWAY HYPERRESPONSIVENESS - Disclosed herein are compounds, compositions and methods for modulating the expression of STAT 6 in a cell, tissue, or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of STAT 6, airway hyperresponsiveness, and/or pulmonary inflammation. | 2009-07-30 |
20090191134 | Stable aerosol pharmaceutical formulations - The present invention provides a stable aerosol pharmaceutical formulation of a beta-agonist, an anticholinergic, or a combination thereof in combination with a cosolvent and optionally a surfactant. The invention also provides a method of making the stable aerosol pharmaceutical formulation and methods of treating bronchoconstriction, asthma and related conditions with the stable aerosol pharmaceutical formulation of the present invention. | 2009-07-30 |
20090191135 | METHODS FOR THE DISPERSION OF WATER-SOLUABLE OR HYDROPHILIC SUBSTANCES IN A SUPERCRITICALLY PRESSURIZED FLUID - A method for encapsulating an active principle by dispersing the active principle in a supercritical fluid by adding a surfactant to the fluid. The surfactant is a block copolymer having at least one CO | 2009-07-30 |
20090191136 | USE OF ACTIVE SUBSTANCE COMPLEXES OF PANTHENOL, GLYCEROL, CITRATE AND/OR BISABOLOL AGAINST POLLEN ALLERGIES - A cosmetic or dermatological preparation for combating or substantially preventing pollen allergies. The preparation comprises panthenol, glycerol and at least one of citrate and bisabolol and has at least one of (i) a pH of from about 4.6 to about 5.4, (ii) a mass ratio of panthenol to citrate of from about 25:1 to about 5:1, based on citrate anion, and (iii) a mass ratio of panthenol to bisabolol of from about 5:1 to about 1:1. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way. | 2009-07-30 |
20090191137 | Method and Material for Controlling or Eliminating Potentially Harmful, Contaminating or Nuisance Micro-Organisms or Cells - A method is shown for reducing or eliminating the levels or activities of potentially harmful or contaminating organisms or cells by applying nanophase manganese (VII) oxide to solutions, surfaces or materials to eliminate, reduce or prevent the growth of potentially harmful, contaminating or undesirable microorganisms, such as algae and bacteria. | 2009-07-30 |
20090191138 | NOVEL TOPICAL FORMULATIONS FOR IMPROVING THE APPEARANCE OF NAILS - A method is provided for improving the appearance of nails of a patient wherein a composition is topically applying to the patient's nail(s) exhibiting symptoms of at least one condition selected from the group consisting of onycholysis, onychoschizia or onychorrhexis and wherein the composition contains one or more biocompatible organic solvents, a polar lipid, a surfactant, water, urea and a thickener wherein the organic solvents include an ester and/or a dihydric and/or polyhydric alcohol is provided. | 2009-07-30 |
20090191139 | WATER BASE SLURRY COMPOSITION FOR COSMETIC PRODUCTS AND METHODS OF USE - This invention relates to water based slurry compositions of cosmetic and personal care products and methods of making and using water based slurry compositions for cosmetic and personal care products such as foundations, eye shadows, lotions, and creams. | 2009-07-30 |
20090191140 | MAKE-UP POWDER, AND PROCESS FOR ITS PREPARATION - Disclosed are cosmetic powders comprising:
| 2009-07-30 |
20090191141 | HAIR CARE COMPOSITIONS AND METHODS OF TREATING HAIR USING SAME - The present invention provides kits and methods for treating hair on the scalp comprising non-toxic compositions providing beneficial effects on hair without employing high temperatures, free radical initiators or rinsing hair after applying the compositions. | 2009-07-30 |
20090191142 | PROCESS FOR LIGHTENING DIRECT DYEING OR OXIDATION DYEING IN THE PRESENCE OF AT LEAST ONE ORGANIC AMINE, DEVICE THEREFOR AND ANHYDROUS COMPOSITION - A process for dyeing human keratin fibers in the presence of at least one oxidizing agent, comprising applying to the fibers at least one anhydrous composition (A) comprising at least one fatty substance and at least one surfactant, at least one composition (B) comprising at least one oxidizing agent, and at least one composition (C) comprising at least one dye chosen from direct and oxidation dyes, and at least one organic amine having a pKb at 25° C. of less than 12. The present disclosure also relates to a multi-compartment device containing, in separate compartments, the compositions (A), (B), and (C); and a method of making a ready-to-use composition. The present disclosure also relates to an anhydrous composition comprising at least one fatty substance, at least one surfactant, at least one dye, and at least one organic amine. | 2009-07-30 |
20090191143 | HAIR SHAPING KIET AND PROCESS COMPRISING AT LEAST ONE NON-HYDROXIDE BASE - The disclosure provides ready-to-use cosmetic compositions for permanently shaping keratin fibers comprising, as permanent hair-shaping active agent, a base not belonging to the hydroxide family. The disclosure also provides kits comprising compartments to be placed in contact to form the ready-to-use compositions, and processes using these compositions. | 2009-07-30 |
20090191144 | USE OF LIPID COMPONENTS AGAINST POLLEN ALLERGIES - A cosmetic or dermatological preparation for combating or substantially preventing pollen allergies. The preparation comprises or essentially consists of a lipid phase which comprises one or more lipids and has a spreading coefficient of less than about 800 mm | 2009-07-30 |
20090191145 | ADHESIVE SYSTEMS CONTAINING POLYISOCYANATE PREPOLYMERS AND ASPARTATE-ESTER CURING AGENTS, PROCESSES FOR PREPARING THE SAME, MEDICAL USES THEREFOR AND DISPENSING SYSTEMS FOR THE SAME - Adhesive systems comprising: (A) an isocyanate group-containing prepolymer prepared by reacting: (A1) an aliphatic isocyante; and (A2) a polyol having a number average molecular weight of ≧400 g/mol and 2 to 6 OH groups; and (B) a curing component comprising: (B1) an amino group-containing aspartate ester of the general formula (I); | 2009-07-30 |
20090191146 | METHODS FOR THE MODULATION OF NEOVASCULARIZATION AND/OR THE GROWTH OF COLLATERAL ARTERIES AND/OR OTHER ARTERIES FROM PREEXISTING ARTERIOLAR CONNECTIONS - Described is the modulation of the neovascularization and/or growth of collateral arteries and/or other arteries from preexisting arteriolar connections. Methods are provided for enhancing neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting organs, tissue or cells with a colony stimulating factor (CSF) or a nucleic acid molecule encoding said CSF. Furthermore, the use of a CSF or a nucleic acid molecule encoding said CSF for the preparation of pharmaceutical compositions for enhancing neovascularization and/or collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections is described. Also provided are methods for the treatment of tumors comprising contacting an organ, tissue or cells with an agent which suppresses neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the inhibition of the biological activity of CSFs. Described is further the use of an agent which suppresses neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through inhibition of the biological activity of CSFs for the preparation of pharmaceutical compositions for the treatment of tumors. | 2009-07-30 |
20090191147 | Use of Interleukin-11 to Prevent Immune-Mediated Cytotoxicity - The use of interleukin-11 to prevent, to ameliorate, and to treat an immune-mediated disease in a mammal in need of such treatment is disclosed. | 2009-07-30 |
20090191148 | CYTOKINE MUTEINS - The present invention relates generally to the treatment of an interleukin-11 (IL-11)-mediated condition. More particularly, the present invention provides the use of modified forms of IL-11 which modulate IL-11 signaling in the treatment of IL-11-mediated conditions. | 2009-07-30 |
20090191149 | IL-1alpha IMMUNIZATION INDUCES AUTOANTIBODIES PROTECTIVE AGAINST ATHEROSCLEROSIS - Immunization of a mammal with IL-1α, which causes the mammal to generate IL-1α autoantibodies, can be used to reduce the risk and severity of, or to reduce progression of, an atherosclerosis-related disease in the mammal. Progression of atherosclerosis-related diseases such as peripheral ischemic heart disease, coronary artery disease, cerebrovascular disease, and peripheral arterial disease can be reduced using this treatment. | 2009-07-30 |
20090191150 | METHODS OF TREATING INFECTIONS USING IL-21 - Methods for treating mammals with infections, particularly viral infections using molecules that have an IL-21 functional activity are described. The molecules having functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known antimicrobial or antiviral therapeutics. | 2009-07-30 |
20090191151 | TRIAZOLE-CONTAINING MACROCYCLIC HCV SERINE PROTEASE INHIBITORS - The present invention discloses compounds of formula I, II and III or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2009-07-30 |
20090191152 | INTRALYMPHATIC CHEMOTHERAPY DRUG CARRIERS - A chemotherapeutic composition can be configured for subcutaneous administration for preferential intralymphatic accumulation while also providing a therapeutic systemic concentration that is not toxic. The composition can include a pharmaceutically acceptable carrier, and a nanoconjugate configured for preferential intralymphatic accumulation after subcutaneous administration. The nanoconjugate can include a nanocarrier configured for preferential intralymphatic accumulation after subcutaneous or interstitial administration, and a plurality of chemotherapeutic agents coupled to the nanocarrier. The nanoconjugate can have a dimension of about 10 nm to about 50 nm. Also, the nanoconjugate can be loaded with the chemotherapeutic agents from about 10% to about 50% w/w. The nanocarrier can be a hyaluronan polymer of about 3 kDa to about 50 kDa. Alternatively, the nanocarrier can be a dendrimer. | 2009-07-30 |
20090191153 | OXIMYL MACROCYCLIC DERIVATIVES - The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2009-07-30 |
20090191154 | ASSEMBLY AND FOLDING OF FC-INTERFERON-BETA FUSION PROTEINS - Disclosed are Fc-interferon-beta (Fc-IFN-β) fusion proteins and nucleic acid molecules encoding them. The Fc-IFN-β fusion proteins include variants of the interferon-beta (IFN-β) protein that are altered to achieve enhanced biological activity, prolonged circulating half-life and greater solubility. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins and/or nucleic acid molecules for treating diseases and conditions alleviated by the administration of interferon-beta. | 2009-07-30 |
20090191155 | COMPOSITIONS AND METHODS FOR AMELIORATING MYOSIN VIIA DEFECTS - The invention provides compositions and methods for ameliorating defects in myosin VIIa (MYO7A) expression and/or function, including providing vectors for myosin VIIa expression and formulations comprising them, and methods of using them, for treating human retinitis pigmentosa (or retinal degeneration), and blindness and deafness such as that found in Usher syndrome. The invention provides in vivo gene therapy for ameliorating defects in myosin VIIa (MYO7A) expression and/or function, including compositions and methods for gene transfer of the human myosin VIIa (MYO7A) gene (the MYO7A gene. | 2009-07-30 |
20090191156 | GM-CSF COSMECEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF - It has been discovered that granulocyte macrophage colony stimulating factor (“GM-CSF”) promotes migration of activated (but not differentiating) keratinocytes to wound sites. It was also discovered that GM-CSF increases the quantity and improves the quality of collagen. This growth factor specifically increases migration of keratinocytes of the “wound” phenotype but does not have significant effects upon differentiated keratinocytes. Examples demonstrate reversal of skin impairment in multiple animal models of diabetic skin imparment when provided in an effective amount over an effective time period. The examples also demonstrate the efficacy of the formulations in cosmetic applications. A preferred formulation is a sustained release formulation that delivers sufficient growth factor to the skin and the underlying tissue thereof to increase the rate of keratinocyte migration, as well as collagen deposition and fibroblast proliferation, in the skin to promote rejuvenation of skin injuries resistant to repair due to underlying disease, such as diabetes, or aging. | 2009-07-30 |
20090191157 | USE OF RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) FOR THE TREATMENT OF TYPE 1 HYPERSENSITIVITY IN A LIVING ANIMAL INCLUDING HUMANS - The present invention relates to the use of a recombinant modified vaccinia virus Ankara (MVA) comprising a heterologous nucleic acid for the production of a medicament for the prevention and/or treatment of type I hypersensitivity in a living animal including humans. The invention further relates to a recombinant modified vaccinia virus Ankara (MVA) comprising a heterologous nucleic acid, wherein the heterologous nucleic acid is incorporated into a non-essential region of the genome of the MVA, the heterologous nucleic acid is under the control of, e.g. a vaccinia virus-specific promoter and, the heterologous nucleic acid is selected from the group of nucleic acids encoding an allergen selected from the group of weed pollens, grass pollens, tree pollens, mites, animals, fungi, insects, rubber, worms, human autoallergens, and foods. | 2009-07-30 |
20090191158 | DEFECTIVE INTERFERING VIRUS - Cloned, i.e. defined, defective interfering (DI) influenza A virus is produced in embryonated hens eggs using a method which generates large quantities of DI virus material. Cloned DI virus is then used in tests on mice and ferrets given a lethal challenge of wild-type influenza A virus. When cloned DI influenza A virus is co-administered with a lethal dose of virulent influenza A virus, mice are protected compared to a control of inactivated cloned DI influenza A virus. Mice which survived the administration of cloned DI influenza A virus and infective challenge virus are three weeks later still protected against lethal challenge with infective virus. Control mice which received only cloned DI influenza A virus and no lethal challenge are not protected three weeks later on lethal challenge with infective virus. | 2009-07-30 |
20090191159 | Multipotent/pluripotent cells and methods - Described herein are multipotent stem cells, e.g., human and other mammalian pluripotent stem cells, and related methods. | 2009-07-30 |
20090191160 | Methods of producing pluripotent stem-like cells - The instant invention provides methods and compositions for the production and use of pluripotent stem-like cells from somatic cells, e.g., fibroblasts. | 2009-07-30 |
20090191161 | TENOCYTE CELL CULTURING METHOD - The present invention relates to a method for culturing tenocytes. In particular the present invention relates to a method for culturing tenocytes comprising the step of incubating tenocytes in a culture medium comprising insulin or functional derivative. | 2009-07-30 |
20090191162 | Catecholamine Receptor Modulation - The invention relates to receptors of catecholamines and their role in stem cell development and function. | 2009-07-30 |
20090191163 | Primed tissue for tissue engineering and methods of priming tissue - Provided is a composition comprising a primed engineered tissue construct, methods of making the composition, methods of using the composition in dermatologic surgery, and a kit for supplying surgical tissue graft components. | 2009-07-30 |
20090191164 | HUMAN HEMATOPOIETIC MULTIPOTENT PROGENITOR CELLS - A substantially enriched human multipotent progenitor cell population is provided, which is characterized as a progenitor cell capable of giving rise to the multipotent lineage but which lacks certain long-term self-renewal properties of the hematopoietic stem cell. Methods are provided for the isolation and culture of these cells. The cell enrichment methods employ reagents that specifically recognize CD34, CD38, CD90 and CD45RA, in conjunction with lineage specific markers. These cells give rise to all types of hematopoietic cells, e.g. myeloid and lymphoid cells, in vivo. | 2009-07-30 |
20090191165 | FIBRIN GLUE COMPOSITION FOR REPAIRING NERVE DAMAGE AND METHODS THEREOF - A fibrin glue composition is for repairing nerve damage, and/or enhancing the functional recovery of a damaged nerve which includes fibrin glue and an amount of bone marrow stem cells (BMSCs) effective for repairing the nerve damage and/or enhancing at least partially the functional recovery. A method is also for repairing nerve damage, and/or enhancing the functional recovery of a damaged nerve in a subject which includes topically applying to the damaged nerve the fibrin glue composition of the invention. | 2009-07-30 |
20090191166 | SCREENING AND THERAPY FOR LYMPHATIC DISORDERS INVOLVING THE FLT4 RECEPTOR TYROSINE KINASE (VEGFR-3) - The present invention provides materials and methods for screening for and treating hereditary lymphedema in human subjects. | 2009-07-30 |
20090191167 | ADULT SERTOLI CELLS AND USES THEREOF - The invention relates, in part, to non-neonatal Sertoli cells derived from non-rodent animals, pharmaceutical compositions comprising such Sertoli cells, and uses thereof. The non-neonatal, non-rodent Sertoli cells express more FasL than neonatal Sertoli cells, and they provide greater immunoprivilege than neonatal Sertoli cells. In some embodiments the Sertoli cells are modified to express a biological factor. In other embodiments, the pharmaceutical compositions further comprise non-Sertoli cells. The invention also provides implantation devices comprising the pharmaceutical compositions, methods of making the pharmaceutical compositions, and methods of using the pharmaceutical compositions by administering an effective amount of the compositions. | 2009-07-30 |
20090191168 | Pregnancy-Induced Oligodendrocyte Precursor Cell Proliferation Regulated by Prolactin - The present invention relates to a method to increase oligodendrocytes and oligodendrocyte precursor cells through administration of prolactin or a prolactin inducing agent. | 2009-07-30 |
20090191169 | Methods for gene transfer to mammals - To provide a transformed hair follicle and a method for transferring a gene to a mammal by means of the transformed hair follicle. | 2009-07-30 |
20090191170 | Nucleic acid compositions and methods of introducing nucleic acids into cells - The invention relates to a bifunctional nucleic acid which includes a first nucleic acid which comprises an aptamer bonded to a second nucleic acid that possesses a biological activity (herein referred to as a “biological effector sequence”) and which is not a nucleic acid ligand. | 2009-07-30 |
20090191171 | Reprogramming of Differentiated Progenitor or Somatic Cells Using Homologous Recombination - The present invention provides methods and compositions for reprogramming somatic cells to a more primitive state, such as induced pluripotent stem cells, using homologous recombination. The induced pluripotent stem cells generated by the methods of the present invention are useful in a variety of therapeutic applications in the treatment and prevention of diseases and disorders. | 2009-07-30 |
20090191172 | Method of Controlling Administration of Cancer Antigen - The present invention is directed to mammalian bi-specific T cells and methods for using these bi-specific T cells. More specifically, the invention relates to a method of controlling administration of cancer antigen to a subject by providing bi-specific T cells that express a viral antigen T cell receptor and a cancer antigen-specific chimeric receptors and triggering their activation by also administering antigen-presenting T-cells which express viral antigen. These bi-specific T cell clones are a source of effector cells that persist in vivo in response to stimulation with viral antigen, leading to long-term function after their transfer to patients with cancer and autoimmune diseases. | 2009-07-30 |
20090191173 | Induction Of Neurogenesis And Stem Cell Therapy In Combination With Copolymer 1 - A method for inducing and enhancing neurogenesis and/or oligodendrogenesis from endogenous as well as from exogenously administered stem cells comprises administering to an individual in need thereof an agent selected from the group consisting of Copolymer 1, a Copolymer 1-related polypeptide, a Copolymer 1-related peptide, and activated T cells which have been activated by Copolymer 1, a Copolymer 1-related polypeptide, or a Copolymer 1-related peptide. The method is particularly useful for stem cell therapy in combination with the agent. | 2009-07-30 |
20090191174 | BLOOD PROCESSING DEVICE AND ASSOCIATED SYSTEMS AND METHODS - The present invention is directed to an environmentally closed cell processing device, for the aseptic processing of blood cells. The device includes a continuous flow centrifuge, fluid reservoirs and fluid handling systems. Blood cells are processed by the present device, to remove their immunodominant antigens. Seroconverted cells and methods of treating subjects with these cells are also described. | 2009-07-30 |
20090191175 | THERAPEUTIC METHODS USING PEG-CONJUGATED AGENTS AND DEVICES FOR PERFORMING THE SAME - The present invention discloses methods and devices for selectively removing anti-PEG antibodies from a patient's blood prior to administration of a PEG-conjugated therapeutic agent so as to prevent immune reactions against the PEG-conjugated therapeutic agents when the agents are administered as a therapeutic regimen. Removal of anti-PEG antibodies may be physical, in which anti-PEG antibodies are physically removed from the blood through an extracorporeal blood circuit connected to an anti-PEG antibody removal device, or functional, in which an anti-PEG inactivating agent is infused into the patient's blood stream prior to administration of the PEG-conjugated therapeutic agent. Also disclosed is a device for selectively removing anti-PEG antibodies from a blood stream and system incorporating the device. | 2009-07-30 |
20090191176 | Chondroitin sulfate synthesis promoter - The invention provides a chondroitin sulfate synthesis promoter useful for the treatment of diseases such as articular disease and discopathy. The chondroitin sulfate synthesis promoter contains, as an active ingredient, chondroitin sulfate glucuronyltransferase protein and/or chondroitin sulfate N-acetylgalactosaminyltransferase-1 protein, or a gene encoding the enzyme protein(s). | 2009-07-30 |
20090191177 | Enantiomerically Pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-A]pyrimidin-9-yl)et- hylamino]benzoic Acid, Its Use In Medical Therapy, And A Pharmaceutical Composition Comprising It - 026 - The present invention relates to enantiomerically pure (−) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl)ethylamino]benzoic acid or pharmaceutically acceptable salts thereof, it being in a solid state, its use in medical therapy, pharmaceutical composition comprising it, its use in the preparation of a medicament for use in a method for preventing or treating diseases, and its use in method for preventing or treating disease. The present invention relates to a selective inhibitor of phosphoinositide (PI) 3-kinase β and use of the selective inhibitor in e.g. anti-thrombotic therapy. | 2009-07-30 |
20090191178 | Manufacture of Highly Phosphorylated Lysosomal Enzymes and Uses Thereof - This invention provides compositions of highly phosphorylated lysosomal enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases. | 2009-07-30 |
20090191179 | Use of factor VIIa analogues with increased activity - The invention relates to methods for the treatment of a severely bleeding subject. | 2009-07-30 |
20090191180 | Use of Factor VIIa Analogues with Increased Activity - The invention relates to methods for treatment of bleeding episodes in a subject with thrombocytopenia. | 2009-07-30 |
20090191181 | METHODS OF MODULATING SMYD3 FOR TREATMENT OF CANCER - The present invention features a method for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of retinoblastoma by SMYD3. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified. N-terminal truncated forms of SMYD3 (alias ZNFN3A1) have higher methylating activity. Lys 824 is a preferred methylation site on the RB1 protein for SMYD3. | 2009-07-30 |
20090191182 | Compositions, Kits, and Methods for the Modulation of Immune Responses Using Galectin-1 - The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma. Accordingly, the invention relates to compositions, kits, and methods for detecting, characterizing, modulating, preventing, and treating immune disorders, e.g., Hodgkin lymphoma. | 2009-07-30 |
20090191183 | SUBSTITUTED INDOLES - Disclosed herein are substituted indole cysteinyl leukotriene receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof. | 2009-07-30 |
20090191184 | DcR3 polypeptide, A TNFR homolog - A TNFR homolog, identified as DcR3, is provided. Nucleic acid molecules encoding DcR3, chimeric molecules and antibodies to DcR3 are also provided. | 2009-07-30 |
20090191185 | Reducing Cancer Cell Invasion Using an Inhibitor of Toll Like Receptor Signaling - Provided herein are methods and compositions for reducing the invasiveness of cancer cells. Such methods and compositions are particularly useful for cancer cells that express a member of the Toll Like Receptor9 (TLR9) subfamily and are useful in selecting the proper treatment for a subject with cancer. | 2009-07-30 |
20090191186 | Antibodies to the PcrV Antigen of Pseudomonas aeruginosa - The current invention provides high-affinity antibodies to the | 2009-07-30 |
20090191187 | ANTIBODIES AGAINST INTERLEUKIN-1 RECEPTOR AND USES THEREOF - The present invention relates to antibodies against interleukin-1 receptor (IL-1R), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. The antibodies of the present invention are particularly useful for treating a variety of inflammatory diseases including, but not limited to, rheumatoid arthritis. | 2009-07-30 |
20090191188 | IMMUNOSTIMULATORY NUCLEIC ACIDS - The invention relates to immunostimulatory nucleic acid compositions and methods of using the compositions. The T-rich nucleic acids contain poly T sequences and/or have greater than 25% T nucleotide residues. The TG nucleic acids have TG dinucleotides. The C-rich nucleic acids have at least one poly-C region and/ore greater than 50% c nucleotides. These immunostimulatory nucleic acids function in a similar manner to nucleic acids containing CpG motifs. The invention also encompasses preferred CpG nucleic acids. | 2009-07-30 |
20090191189 | REPLIKIN PEPTIDES IN RAPID REPLICATION OF GLIOMA CELLS AND IN INFLUENZA EPIDEMICS - Peptides of influenza virus hemagglutinin protein and | 2009-07-30 |
20090191190 | Anti-ABeta Globulomer Antibodies, Antigen-Binding Moieties Thereof, Corresponding Hybridomas, Nucleic Acids, Vectors, Host Cells, Methods of Producing Said Antibodies, Compositions Comprising Said Antibodies, Uses Of Said Antibodies And Methods Of Using Said Antibodies - Anti-Aβ globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies. | 2009-07-30 |
20090191191 | Methods for the Modulation of IL-13 - The present invention is drawn to methods for modulating IL-13 expression and/or activity in a mammal comprising administering an effective amount of an agent which modulates the expression and/or activity of IL-9. | 2009-07-30 |
20090191192 | HUMANIZED ANTI-CCR2 ANTIBODIES AND METHODS OF USE THEREFOR - The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods. | 2009-07-30 |
20090191193 | Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof - Compounds useful as antiproliferative agents, including, for example, anticancer agents, according to formula I: | 2009-07-30 |
20090191194 | INHIBITION OF PROTEIN KINASE C ALPHA FOR THE TREATMENT OF CARDIOVASCULAR DISEASES - The invention relates to the use of agents impeding the expression and/or activity of protein kinase C-alpha (PKC-α), especially for treatment of patients with diabetes and complications such as diabetic nephropathy, retinopathy or neuropathy. | 2009-07-30 |
20090191195 | Combination of FcgammaRIIB-Specific Antibodies and CD20-Specific Antibodies and Methods of Use Thereof - The present invention relates to methods of treatment, prevention, management or amelioration of one or more symptoms of diseases or disorders associated with CD20 expression that encompass administration of a combination of: (A) one or more antibodies that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies bind FcγRIIA, and (B) one or more antibodies that specifically bind to CD20. Such methods include methods of treating, preventing, managing or ameliorating one or more symptoms of a B cell related disease or disorder or an inflammatory disorder. The invention also provides pharmaceutical compositions comprising an anti-FcγRIIB antibody and an anti-CD20 antibody. | 2009-07-30 |
20090191196 | USE - The invention describes the use of an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis, and the use of a compound which depletes serum amyloid P component from the circulation in combination with an antibody specific for serum amyloid P component. | 2009-07-30 |
20090191197 | CANCEROUS DISEASE MODIFYING ANTIBODIES - The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells. | 2009-07-30 |
20090191198 | METHODS FOR BLOCKING THE INTERACTION BETWEEN NKP80 AND ITS LIGANDS - The present invention relates to applications based on the findings of the interaction between NKp80 and its ligand AICL. A method of treating or preventing inflammatory diseases in a subject is disclosed, comprising administering a substance blocking the interaction between NKp80 and AICL, in particular for treating autoimmune diseases. Preferably, the substance is selected from the group comprising anti-NKp80-antibodies, anti-AICL-antibodies, soluble NKp80, soluble AICL, or functional fragments thereof. | 2009-07-30 |
20090191199 | GLYCOENGINEERED, RECOMBINANT ANTIBODY - The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof. | 2009-07-30 |
20090191200 | Method for the Treatment of Multiple Sclerosis by Inhibiting IL-17 Activity - The present invention provides a method for the treatment and/or prophylaxis of multiple sclerosis (MS) comprising administering a therapeutically effective amount of an inhibitor of IL-17 activity. | 2009-07-30 |
20090191201 | Combination of the application of antibodies for immunostimulation together with glucocorticoids - The present invention relates to methods for reducing or eliminating the non-specific release of a cytokine associated with a disease comprising administering at least one glucocorticoid and an immunostimulating antibody. Additionally, the present invention relates to a pharmaceutical composition that contains at least one immunostimulating antibody and at least one glucocorticoid. | 2009-07-30 |
20090191202 | Methods for manipulating phagocytosis mediated by CD47 - Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. circulating hematopoietic cells, bone marrow cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is desirable. In other embodiments the circulating cells are leukemia cells, particularly acute myeloid leukemia (AML), where increased phagocytosis is desirable. | 2009-07-30 |
20090191203 | Bcma Polypeptides And Uses Thereof - The present invention relates to BCMA polypeptide variants and their uses, particularly for therapeutic or prophylactic treatment in human subjects. The invention also relates to nucleic acids encoding said polypeptides, vectors comprising such nucleic acids and recombinant cells containing the same. The invention further discloses methods of producing such polypeptides, as well as methods and tools for detecting or dosing these polypeptides in any sample. | 2009-07-30 |
20090191204 | ANTI-PSGL-1 ANTIBODIES - Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject. | 2009-07-30 |
20090191205 | Compositions and Methods for Treating and Diagnosing Cancer - The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells. | 2009-07-30 |
20090191206 | Human Semen Enhancer of Viral Infection Peptides (SEVI) and Their Use - Subject of the invention are peptides corresponding to a fragment of amino acids 240-290 of human prostatic acid phosphatase. The invention also relates to nucleic acids, antibodies, medicaments and diagnostics and their use and use of the peptides for the treatment and diagnosis of viral diseases, especially HIV disease. | 2009-07-30 |
20090191207 | COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS OR TREATMENT OF VIRAL DISEASES - The invention relates to the use preferably of at least one active ingredient for the prophylaxis or therapy of a viral disease, wherein this active ingredient inhibits at least one component of the cellular signal transduction pathway for the activation of the transcription factor NF-kB such that virus multiplication is inhibited. The present invention relates furthermore to the local, preferably aerogenic, administration of the active ingredient according to the invention for inhibiting virus multiplication. The active ingredient according to the invention may be combined with at least one further antivirally effective substance for the prophylaxis or therapy of a viral disease. | 2009-07-30 |
20090191208 | Antibodies against flagellin and uses thereof - The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, | 2009-07-30 |
20090191209 | METHODS AND COMPOSITIONS FOR TARGETING POLYUBIQUITIN - Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided. | 2009-07-30 |
20090191210 | Method for inhibiting tumor invasion or spreading in a subject - The present invention provides for a method for inhibiting tumor invasion or metastasis in a subject which comprises administering to the subject a therapeutically effective amount of a form of soluble Receptor for Advanced Glycation Endproducts (RAGE). The present invention also provides a method for evaluating the ability of an agent to inhibit tumor invasion in a local cellular environment which comprises: (a) admixing with cell culture media an effective amount of the agent; (b) contacting a tumor cell in cell culture with the media from step (a); (c) determining the amount of spreading of the tumor cell culture, and (d) comparing the amount of spreading of the tumor cell culture determined in step (c) with the amount determined in the absence of the agent, thus evaluating the ability of the agent to inhibit tumor invasion in the local cellular environment. The present invention also provides a pharmaceutical composition which comprises a therapeutically effective amount of the agent evaluated in the aforementioned method and a pharmaceutically acceptable carrier. | 2009-07-30 |
20090191211 | METHODS FOR DAMAGING CELLS USING EFFECTOR FUNCTIONS OF ANTI-EphA4 ANTIBODIES - The present invention relates to the use of cytoxicity based on the effector function of anti-EphA4 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-EphA4 antibody as an active ingredient for damaging EphA4-expressing cells using antibody effector function. Since EphA4 is strongly expressed in pancreatic cancer cells, the present invention is particularly useful in pancreatic cancer therapies. | 2009-07-30 |
20090191212 | Angiopoietin-2 Specific Binding Agents - Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies. | 2009-07-30 |
20090191213 | Compositions and methods for regulating NK cell activity - The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects. | 2009-07-30 |
20090191214 | ANTI-HUMAN IL-21 MONOCLONAL ANTIBODIES - Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells T | 2009-07-30 |
20090191215 | Treatment with anti-VEGF Antibodies - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. | 2009-07-30 |
20090191216 | Antibody or a fragment thereof, having neutralizing activity against HIV - The invention relates to a monoclonal antibody or a fragment thereof, recognizing a peptide of sequence set forth as SEQ ID NO 7 or an analogue thereof, wherein the complementarity determining region 3 (CDR3) of its H chain variable region comprises the peptide sequence set forth as SEQ ID NO 1 or a functional analogue thereof. | 2009-07-30 |
20090191217 | Anti-IL-1R1 Single Domain Antibodies And Therapeutic Uses - Disclosed is the use of an antagonist of Interleukin 1 receptor type 1 (IL-1R1) for the manufacture of a medicament treating, preventing or suppressing lung inflammation or a respiratory disease. In some embodiments of the described invention, the medicament is for local administration to pulmonary tissue. Also disclosed are methods for treating lung inflammation or a respiratory disease. | 2009-07-30 |